C4 Therapeutics, Inc. (CCCC)
3.50
-0.01
(-0.28%)
USD |
NASDAQ |
Sep 14, 11:26
C4 Therapeutics Enterprise Value : 234.59M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 234.59M |
| September 10, 2026 | 221.07M |
| September 09, 2026 | 225.99M |
| September 08, 2026 | 239.51M |
| September 04, 2026 | 265.32M |
| September 03, 2026 | 262.86M |
| September 02, 2026 | 269.01M |
| September 01, 2026 | 278.84M |
| August 31, 2026 | 259.18M |
| August 28, 2026 | 276.38M |
| August 27, 2026 | 307.11M |
| August 26, 2026 | 324.32M |
| August 25, 2026 | 319.40M |
| August 24, 2026 | 307.11M |
| August 21, 2026 | 294.82M |
| August 20, 2026 | 298.51M |
| August 19, 2026 | 320.63M |
| August 18, 2026 | 316.94M |
| August 17, 2026 | 327.39M |
| August 14, 2026 | 324.32M |
| August 13, 2026 | 304.65M |
| August 12, 2026 | 282.53M |
| August 11, 2026 | 278.84M |
| August 10, 2026 | 248.11M |
| August 07, 2026 | 261.63M |
| Date | Value |
|---|---|
| August 06, 2026 | 250.57M |
| August 05, 2026 | 248.11M |
| August 04, 2026 | 246.88M |
| August 03, 2026 | 233.37M |
| July 31, 2026 | 230.91M |
| July 30, 2026 | 253.03M |
| July 29, 2026 | 235.82M |
| July 28, 2026 | 239.51M |
| July 27, 2026 | 244.43M |
| July 24, 2026 | 221.07M |
| July 23, 2026 | 251.80M |
| July 22, 2026 | 262.86M |
| July 21, 2026 | 273.92M |
| July 20, 2026 | 243.20M |
| July 17, 2026 | 256.72M |
| July 16, 2026 | 243.20M |
| July 15, 2026 | 270.24M |
| July 14, 2026 | 271.47M |
| July 13, 2026 | 284.99M |
| July 10, 2026 | 302.19M |
| July 09, 2026 | 330.46M |
| July 08, 2026 | 318.17M |
| July 07, 2026 | 337.84M |
| July 06, 2026 | 312.02M |
| July 02, 2026 | 331.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 1.572B |
| Rallybio Corp. | -3.295M |
| Q32 Bio, Inc. | 162.50M |
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Oncolytics Biotech, Inc. | 89.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.64M |
| Revenue (Quarterly) | 6.641M |
| Total Expenses (Quarterly) | 30.28M |
| EPS Diluted (Quarterly) | -0.1808 |
| Gross Profit Margin (Quarterly) | 73.05% |
| Profit Margin (Quarterly) | -355.9% |
| Earnings Yield | -28.54% |
| Normalized Earnings Yield | -25.58 |